title: Effect of subcutaneous butylscopolamine administration in the reduction of peristaltic artifacts in 1.5-T MR fast abdominal examinations.
abstract: In abdominal MR imaging, ghost artifacts from noncyclic bowel movements can reduce the quality of the images. Although pharmacologic suppression of motion is effective, no study has being conducted to analyze the influence of drug motion suppression on fast breath-hold 1.5-T examinations of the upper abdomen. A prospective, randomized, double-blind trial was conducted in 50 patients. Patients were randomly distributed into two groups: The control group received only an oral solution, whereas the other group received the oral solution plus a subcutaneous injection of 20 mg of butylscopolamine 10 min before the MR examination. Breath-hold T1-weighted gradient-recalled-echo (GRE) MR images were obtained in a 1.5-T superconductive unit. Quantitative image analysis was performed with region-of-interest (ROI) measurements of the signal intensity of the liver and in background air anterior and lateral to the patient. A qualitative analysis of the subjective quality of the T1-weighted images was also done, and the adverse reactions were registered. The groups were homogeneous regarding age, gender, and weight distribution. No significant differences in the signal intensity of the liver and in the incoherent noise measurements were found between the two groups. Gastrointestinal noise showed significant differences between groups, with lower values for the butylscopolamine group compared with the control group. There was also a statistically significant difference in the image quality between groups, and optimal studies were only found in the butylscopolamine group, where most patients had a good-quality evaluation. Regarding adverse events, there were non-significant differences between groups. In conclusion, administration of an antiperistaltic agent to reduce the movements of the gastrointestinal tract diminishes the motion artifacts generated on MR imaging of the abdomen, even at high field strength and with fast imaging sequences. Images of the upper abdomen obtained after pharmacologic suppression of the gastrointestinal movement are of significantly superior quality.
authors.affiliation: Department of Radiology, Clínica Quirón, Avda. Blasco Ibañez, 14, 46017 Valencia, Spain. rmquironv.cqv@quiron.es
authors.forename: Rosa
authors.initials: R
authors.lastname: Dosdá
authors.forename: Luis
authors.initials: L
authors.lastname: Martí-Bonmatí
authors.forename: Crisanto L
authors.initials: CL
authors.lastname: Ronchera-Oms
authors.forename: Enrique
authors.initials: E
authors.lastname: Mollá
authors.forename: Estanislao
authors.initials: E
authors.lastname: Arana
mesh_terms: D000005:Abdomen / Q000473:pathology*; D000328:Adult; D000368:Aged; D002086:Butylscopolammonium Bromide / Q000008:administration & dosage* / Q000009:adverse effects; D003287:Contrast Media; D004311:Double-Blind Method; D017352:Echo-Planar Imaging; D005260:Female; D019786:Gadolinium DTPA; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D007089:Image Enhancement; D007091:Image Processing, Computer-Assisted; D007279:Injections, Subcutaneous; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010528:Peristalsis / Q000187:drug effects*; D011292:Premedication; D011446:Prospective Studies
chemical_list: D003287:Contrast Media; D002086:Butylscopolammonium Bromide; C064925:gadodiamide; D019786:Gadolinium DTPA